KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EPS (Weighted Average and Diluted) (2016 - 2025)

Sarepta Therapeutics (SRPT) has 11 years of EPS (Weighted Average and Diluted) data on record, last reported at $1.44 in Q2 2025.

  • For Q2 2025, EPS (Weighted Average and Diluted) rose 1958.49% year-over-year to $1.44; the TTM value through Jun 2025 reached $1.44, up 311.9%, while the annual FY2024 figure was $2.34, 140.34% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $1.44 in Q2 2025 per SRPT's latest filing, down from $1.56 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.56 in Q4 2024 and bottomed at -$2.65 in Q2 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.26, with a median of -$0.27 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 159.8% in 2022, then surged 1958.49% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.43 in 2021, then increased by 13.29% to -$1.24 in 2022, then soared by 161.29% to $0.76 in 2023, then surged by 105.26% to $1.56 in 2024, then fell by 7.63% to $1.44 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $1.44 in Q2 2025, $1.56 in Q4 2024, and $0.34 in Q3 2024.